Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.65 (market cap $3.97B), while State Street SPDR S&P Biotech ETF trades at $152.22 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.5× Direxion Daily TSLA Bull 2X Shares's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TSLL | XBI | |
|---|---|---|
Market Cap | $3.97B | $10.11B |
Volume | 38,458,237 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $23.03 | $169.55 |
52-Week Low | $6.74 | $104.99 |
Typical Hold Time | 15 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.56, up 4.04% today, with a neutral technical signal overall despite bullish moving averages. The leveraged ETF amplifies Tesla's daily returns, with recent momentum driven by Tesla's Cybercab event anticipation. Key support sits at $10 with resistance at $11, while RSI indicators show mixed signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF tracking Tesla, TSLL offers amplified exposure but carries significant volatility risks from daily rebalancing effects. The fund's performance remains entirely dependent on Tesla's stock movements, with recent news highlighting both opportunity from Tesla events and the structural risks of holding leveraged products long-term during volatile periods.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
